Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.

Saved in:
Bibliographic Details
Title: Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
Authors: Appelbaum J; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.; Division of Hematology/Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.; Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Seattle Children's Hospital, Seattle, Washington, USA., Price AE; 2seventy bio, Cambridge, Massachusetts, USA., Oda K; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Zhang J; 2seventy bio, Cambridge, Massachusetts, USA., Leung WH; 2seventy bio, Cambridge, Massachusetts, USA., Tampella G; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Xia D; 2seventy bio, Cambridge, Massachusetts, USA., So PP; 2seventy bio, Cambridge, Massachusetts, USA., Hilton SK; 2seventy bio, Cambridge, Massachusetts, USA., Evandy C; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Sarkar S; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Martin U; 2seventy bio, Cambridge, Massachusetts, USA., Krostag AR; 2seventy bio, Cambridge, Massachusetts, USA., Leonardi M; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Zak DE; 2seventy bio, Cambridge, Massachusetts, USA., Logan R; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Lewis P; 2seventy bio, Cambridge, Massachusetts, USA., Franke-Welch S; 2seventy bio, Cambridge, Massachusetts, USA., Ngwenyama N; 2seventy bio, Cambridge, Massachusetts, USA., Fitzgerald M; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Tulberg N; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Rawlings-Rhea S; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Gardner RA; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Jones K; Inhibrx, Torrey Pines Science Park, La Jolla, California, USA., Sanabria A; Inhibrx, Torrey Pines Science Park, La Jolla, California, USA., Crago W; Inhibrx, Torrey Pines Science Park, La Jolla, California, USA., Timmer J; Inhibrx, Torrey Pines Science Park, La Jolla, California, USA., Hollands A; Inhibrx, Torrey Pines Science Park, La Jolla, California, USA., Eckelman B; Inhibrx, Torrey Pines Science Park, La Jolla, California, USA., Bilic S; Vandro Consulting, Waukee, Iowa, USA., Woodworth J; Vandro Consulting, Waukee, Iowa, USA., Lamble A; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.; Seattle Children's Hospital, Seattle, Washington, USA., Gregory PD; 2seventy bio, Cambridge, Massachusetts, USA., Jarjour J; 2seventy bio, Cambridge, Massachusetts, USA., Pogson M; 2seventy bio, Cambridge, Massachusetts, USA., Gustafson JA; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA., Astrakhan A; 2seventy bio, Cambridge, Massachusetts, USA., Jensen MC; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2024 Mar 19; Vol. 134 (9). Date of Electronic Publication: 2024 Mar 19.
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI162593